Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.

J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.

PMID:
31085679
2.

Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF.

Cochrane Database Syst Rev. 2018 Aug 22;8:CD006023. doi: 10.1002/14651858.CD006023.pub3.

PMID:
30132304
3.

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G; FRENCH Study collaborators.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930-1940. doi: 10.2215/CJN.03030317. Epub 2017 Oct 26.

4.

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.

Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutiérrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M.

Clin J Am Soc Nephrol. 2013 Jun;8(6):1009-18. doi: 10.2215/CJN.09250912. Epub 2013 Mar 7.

6.

Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.

Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A.

Nephrol Dial Transplant. 2011 Aug;26(8):2567-71. doi: 10.1093/ndt/gfr144. Epub 2011 Mar 24.

PMID:
21436379
7.

Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.

Ito E, Inaguma D, Koide S, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y.

Clin Exp Nephrol. 2018 Dec;22(6):1309-1314. doi: 10.1007/s10157-018-1584-0. Epub 2018 May 10.

PMID:
29748907
8.

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.

Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, Wolf M.

Nephrol Dial Transplant. 2011 Feb;26(2):584-91. doi: 10.1093/ndt/gfq419. Epub 2010 Jul 14.

9.
10.

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA.

J Am Soc Nephrol. 2015 Oct;26(10):2328-39. doi: 10.1681/ASN.2015020117. Epub 2015 May 12. Review.

11.

The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.

Soriano S, Ojeda R, Rodríguez M, Almadén Y, Rodríguez M, Martín-Malo A, Aljama P.

Clin Nephrol. 2013 Jul;80(1):17-22. doi: 10.5414/CN107764.

PMID:
23391319
12.

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block GA.

Clin J Am Soc Nephrol. 2014 Mar;9(3):543-52. doi: 10.2215/CJN.05170513. Epub 2014 Jan 9.

13.

Effects of phosphate binders in moderate CKD.

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM.

J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19.

14.

Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.

Chang YM, Tsai SC, Shiao CC, Liou HH, Yang CL, Tung NY, Hsu KS, Chen IL, Liu MC, Kao JL, Jhen RN, Huang YT.

Clin Exp Nephrol. 2017 Oct;21(5):908-916. doi: 10.1007/s10157-016-1362-9. Epub 2016 Dec 7. Erratum in: Clin Exp Nephrol. 2017 Feb 23;:.

PMID:
27928636
15.

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM.

Am J Kidney Dis. 2015 May;65(5):728-36. doi: 10.1053/j.ajkd.2014.10.014. Epub 2014 Nov 4.

16.

Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.

Spatz C, Roe K, Lehman E, Verma N.

Nephron Clin Pract. 2013;123(1-2):61-6. doi: 10.1159/000351811. Epub 2013 Jun 14.

17.
18.

Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.

Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A, Go A, Lash J, Kusek J, Grunwald J, Wolf M; CRIC Study Investigators.

Nephrol Dial Transplant. 2015 Sep;30(9):1534-41. doi: 10.1093/ndt/gfv123. Epub 2015 Apr 24.

20.

Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial.

Han N, Hong SH, Kim YS, Kim DK, Kim IW, Ji E, Oh JM.

Ther Clin Risk Manag. 2017 Aug 14;13:999-1007. doi: 10.2147/TCRM.S142564. eCollection 2017.

Supplemental Content

Support Center